Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Interest Expenses: 2010-2025

Historic Interest Expenses for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Sep 2025 value amounting to $8.4 million.

  • Ironwood Pharmaceuticals' Interest Expenses fell 10.46% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.8 million, marking a year-over-year increase of 3.78%. This contributed to the annual value of $33.0 million for FY2024, which is 52.73% up from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Interest Expenses of $8.4 million as of Q3 2025, which was up 0.93% from $8.4 million recorded in Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Interest Expenses peaked at $9.8 million during Q3 2023, and registered a low of $1.5 million during Q3 2022.
  • For the 3-year period, Ironwood Pharmaceuticals' Interest Expenses averaged around $7.2 million, with its median value being $8.4 million (2025).
  • In the last 5 years, Ironwood Pharmaceuticals' Interest Expenses plummeted by 80.81% in 2022 and then soared by 545.60% in 2023.
  • Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' Interest Expenses stood at $8.0 million in 2021, then crashed by 80.81% to $1.5 million in 2022, then surged by 451.97% to $8.4 million in 2023, then grew by 5.83% to $8.9 million in 2024, then dropped by 10.46% to $8.4 million in 2025.
  • Its Interest Expenses was $8.4 million in Q3 2025, compared to $8.4 million in Q2 2025 and $8.1 million in Q1 2025.